NCT01847547已完成不适用
Comparative Effectiveness of Oral Anticoagulants: A Cohort Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,982
- 主要终点
- Incidence Rate of Stroke
研究概览
简要总结
This cohort study plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in patients with non-valvular atrial fibrillation at risk for stroke.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Incidence Rate of Stroke
时间窗: From treatment initiation until end of follow-up; up to 20 months
Events during follow-up (October 2010- 30 June 2012) were identified using ICD 9 codes.
Incidence Rate of Major Bleeding
时间窗: From treatment initiation until end of follow-up; up to 20 months
Events during follow-up (October 2010- 30 June 2012) were identified using ICD 9 and procedure codes.
次要结局
- Incidence Rate of Myocardial Infarction(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Venous Thromboembolism(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Major Urogenital Bleeding(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Major Other Bleeding(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Transient Ischemic Attack(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Major Lower Gastrointestinal Bleeding(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Major Upper Gastrointestinal Bleeding(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Stroke or Systemic Embolism(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Systemic Embolism(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Ischemic Stroke(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Hemorrhagic Stroke(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Stroke Uncertain Classification(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Deep Vein Thrombosis(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Pulmonary Embolism(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Major Intracranial Bleeding(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Major Extracranial Bleeding(From treatment initiation until end of follow-up; up to 20 months)
- Incidence Rate of Major Gastrointestinal Bleeding(From treatment initiation until end of follow-up; up to 20 months)
研究者
相似试验
已完成
不适用
Validation of Predictors of OAC Initiation Using EMR DataAtrial FibrillationNCT03006341Boehringer Ingelheim140,187
招募中
不适用
Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary InterventionAnticoagulantsAtrial FibrillationCoronary Artery DiseaseNCT04977076Zuyderland Medisch Centrum1,270
已完成
不适用
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With MedicareAnticoagulantsObesityAtrial FibrillationNCT04681482Pfizer107,383
招募中
2 期
Comparison of the effects of Rivaroxaban and Apixaban with Heparin and Enoxaparin in patients undergoing gynecological oncological surgery.IRCT20220211053991N1Iran University of Medical Sciences80
已完成
不适用
Direct Oral Anticoagulants and Venous ThromboembolismMajor BleedVenous ThromboembolismNCT02833987Canadian Network for Observational Drug Effect Studies, CNODES59,525